ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2520

Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort

Stefan Krämer1, Kristian Vogt2, Martin Busch3, Tobias Schmitt4, Raoul Bergner5, Sebastian Mosberger5, Thomas Neumann6, Teresa Schreibing1, Fabian Schumbrink1 and Thomas Rauen2, 1Department of Internal Medicine II, RWTH University Hospital Aachen, Aachen, Germany, 2Department of Internal Medicine II, RWTH University Hospital AachenMedicine II, Aachen, Germany, 3Department of Internal Medicine III, University Hospital, Friedrich-Schiller University, Jena, Jena, Germany, 4University Hospital Jena, Friedrich-Schiller University, Department of Internal Medicine III, Jena, Germany, 5Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, 6Department of Rheumatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Nephritis, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2504–2523) Vasculitis – ANCA-Associated Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Glomerulonephritis is a common and threatening manifestation in ANCA-associated vasculitis (AAV). To assess the risk of end-stage kidney disease (ESKD), various scores have been developed, with the ANCA renal risk score (ARRS) and the improved ANCA kidney risk score (AKRiS) [1] being introduced most recently. We aim to investigate its performance in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) separately in comparison to histological finding.

Methods: We retrospectively analyzed 220 AAV cases between 1998 and 2021 who underwent renal biopsies and could be classified according to the 2020 ACR/EULAR criteria as either GPA or MPA. Follow-up visits were recorded every 6 months. The entire follow-up period was screened for the composite renal endpoint, which included death, dialysis, renal transplantation or the development or ESKD persistence with an eGFR < 15 ml/min/1.73 m² at or after six months of follow-up. The cases were analyzed according to histology and different risk scores. Comparison was done by Kaplan-Meier Curves, log-rank test and Herrell’s C.

Results: Histological analysis revealed that renal biopsies from MPA patients showed significantly more sclerosis, interstitial fibrosis and tubular atrophy. In terms of histological classification, most cases fell into focal and mixed classes, which mainly transitioned into low- and medium-risk AKRiS categories. Higher risk classifications predominantly derived from crescentic and sclerotic classes (Fig. 1). The substantial group categorized as medium risk most frequently transitioned to lower risk scores within AKRiS. Kaplan-Meier-plots document a clear stratification for the chosen renal end-point. The comparison of ARRS and AKRiS by ROC and the AUC analyzes revealed slightly higher values of the new AKRiS score with an AUC of 0.76 as opposed to ARRS with an AUC of 0.70 (Tabl. 1). The AUC was consistently slightly higher for MPA than for GPA in both risk scores and generally higher for AKRiS than for ARRS. AKRiS stratification proved effective for predicting the composite renal endpoint (area under the curve ≥0.7, C-Index 0.899). ARRS and AKRiS classified 67.7% of cases into the same risk category, while AKRiS assigned a lower risk category in 24.5% of cases and upgraded to a higher risk category in only 7.7% of cases.

Conclusion: The new AKRiS score was found to be effective not only in predicting ESKD but also in assessing a strong composite renal endpoint in a large European AAV cohort, despite slight differences in histological and event patterns between GPA and MPA under comparable treatment regimen.

Supporting image 1Distribution of histological classification and their transformation into risk classes, color is taken from final AKRiS class to illustrate their origin and flow.

Supporting image 2Histopathological findings and risk scores at diagnosis and outcomes of 220 patients having AAV with renal involvement.

Supporting image 3Kaplan-Meier-plot of the composite renal endpoint for each risk group .


Disclosures: S. Krämer: None; K. Vogt: None; M. Busch: Alexion, 6, AstraZeneca, 6, Boehringer-Ingelheim, 1, 6, Bristol-Myers Squibb(BMS), 6, CSL Vifor, 1, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Novartis, 1, 6, Otsuka, 1, Pfizer, 1, 6, Pharmacosmos, 6; T. Schmitt: None; R. Bergner: AbbVie, 1, 6, Alfasigma, 1, 6, Bristol-Myers Squibb(BMS), 6, Chugai, 6, Eli Lilly, 6, German Rheumatology Society, 12, unpaid board member for Commission für student education, GlaxoSmithKlein(GSK), 1, 6, Janssen, 6, Merck/MSD, 6, Novartis, 1, 6, Vifor, 1, 5; S. Mosberger: None; T. Neumann: Amgen Switzerland AG, 1, AstraZeneca, 1, Boehringer-Ingelheim, 1, Celgene Switzerland, 1, CSL Vifor Switzerland, 1, 6, GlaxoSmithKlein(GSK), 1, 6, Janssen-Cilag AG, 1, Novartis Pharma Schweiz AG, 1, 6, UCB-Pharma AG, 1; T. Schreibing: None; F. Schumbrink: None; T. Rauen: CSL Vifor, 1.

To cite this abstract in AMA style:

Krämer S, Vogt K, Busch M, Schmitt T, Bergner R, Mosberger S, Neumann T, Schreibing T, Schumbrink F, Rauen T. Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evolution-in-risk-stratification-for-renal-outcomes-in-anca-associated-vasculitides-using-established-scores-and-histopathological-criteria-in-a-large-european-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evolution-in-risk-stratification-for-renal-outcomes-in-anca-associated-vasculitides-using-established-scores-and-histopathological-criteria-in-a-large-european-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology